Aytu Biopharma, Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The company's strategy centers on in-licensing, acquiring, developing, and commercializing novel prescription therapeutics to build a portfolio of revenue-generating products. It leverages its commercial team's expertise to establish leading brands within large therapeutic markets, with a current emphasis on the commercialization of EXXUA for major depressive disorder.

Aytu Biopharma, Inc generates revenue primarily through the sale of its prescription pharmaceutical products distributed via third-party wholesalers, distributors, and pharmacies. Its core revenue comes from three product portfolios: EXXUA for the treatment of major depressive disorder, the ADHD Portfolio for attention-deficit/hyperactivity disorder, and the Pediatric Portfolio consisting of legacy pediatric products. The company successfully launched EXXUA in the second quarter of fiscal 2026 as the centerpiece of its commercial efforts, while continuing to commercialize its existing ADHD and Pediatric products.

The company operates through the following segments:

• EXXUA: This segment focuses on the commercialization of EXXUA, a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for the treatment of major depressive disorder in adults. EXXUA is not a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor and has no reuptake inhibition activity. The product is believed to modulate serotonin activity through strong binding affinity for 5HT1a receptors, which are key regulators of mood and emotion.

• ADHD Portfolio: This segment consists of products for the treatment of attention-deficit/hyperactivity disorder, including Adzenys and related formulations. Aytu Biopharma, Inc has entered into international exclusive collaboration, distribution, and supply agreements to commercialize certain ADHD products. The first agreement is with Medomie, a privately owned pharmaceutical company, which will commercialize the ADHD products in Israel and the Palestinian Authority. The second agreement is with Lupin, a subsidiary of global pharmaceutical company Lupin Limited, which will commercialize the ADHD products in Canada.

• Pediatric Portfolio: This segment consists of a line of legacy prescription pediatric products acquired from Cerecor, Inc. in October 2019. The portfolio includes various pediatric formulations that are commercialized through established distribution channels. The company supplies these products to third-party wholesalers and pharmacies for sale to end-users.

Aytu Biopharma, Inc operates in a competitive pharmaceutical industry focused on central nervous system therapeutics, particularly in the major depressive disorder and attention-deficit/hyperactivity disorder markets. The company differentiates itself through EXXUA's unique mechanism of action as the only antidepressant acting on serotonin receptors without a label warning about the risk of sexual dysfunction. Its competitive advantages include a focused commercial strategy, intellectual property protections for key products like Adzenys, and partnerships that expand geographic reach for its ADHD portfolio. The company actively monitors and responds to competitive pressures such as generic entrants, payor pressures, and new branded competitors in its therapeutic markets.

Aytu Biopharma, Inc serves patients suffering from central nervous system disorders, primarily adults with major depressive disorder and children and adolescents with attention-deficit/hyperactivity disorder. Its products are distributed through third-party wholesalers, pharmacies, and healthcare providers who prescribe the medications to patients. The company's ADHD products are also subject to international distribution agreements with partners in Israel, the Palestinian Authority, and Canada, expanding access to patients in those regions.